Growth hormone treatment does not augment the anti-diabetic effects of liraglutide in UCD-T2DM rats

被引:0
|
作者
Swarbrick, Michael M. M. [3 ,4 ,5 ]
Cox, Chad L. L.
Graham, James L. L.
Knudsen, Lotte B. B.
Stanhope, Kimber
Raun, Kirsten
Havel, Peter J. J. [1 ,2 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Nutr, One Shields Ave, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, One Shields Ave, Davis, CA 95616 USA
[3] Univ Sydney, ANZAC Res Inst, Bone Res Program, Concord, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Concord Clin Sch, Sydney, Australia
[5] Novo Nordisk AS, Malov, Denmark
基金
美国国家卫生研究院;
关键词
diabetes mellitus; food intake; growth hormone; insulin; liraglutide; obesity; TYPE-2; DIABETES-MELLITUS; INSULIN-RESISTANCE; PEPTIDE-1; ANALOG; SKELETAL-MUSCLE; GLUCOSE-TOLERANCE; OBESITY; MODEL; ADIPONECTIN; SENSITIVITY; WEIGHT;
D O I
10.1002/edm2.392
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases satiety and enhances insulin secretion. GLP-1 receptor agonists, such as liraglutide, are used therapeutically in humans to improve glycaemic control and delay the onset of type 2 diabetes mellitus (T2DM). In UCD-T2DM rats, a model of polygenic obesity and insulin resistance, we have previously reported that daily liraglutide administration delayed diabetes onset by > 4 months. Growth hormone (GH) may exert anti-diabetic effects, including increasing beta-cell mass and insulin secretion, while disrupting GH signalling in mice reduces both the size and number of pancreatic islets. We therefore hypothesized that GH supplementation would augment liraglutide's anti-diabetic effects.MethodsMale UCD-T2DM rats were treated daily with GH (0.3 mg/kg) and/or liraglutide (0.2 mg/kg) from 2 months of age. Control (vehicle) and food-restricted (with food intake matched to liraglutide-treated rats) groups were also studied. The effects of treatment on diabetes onset and weight gain were assessed, as well as measures of glucose tolerance, lipids and islet morphology.ResultsLiraglutide treatment significantly reduced food intake and body weight and improved glucose tolerance and insulin sensitivity, relative to controls. After 4.5 months, none of the liraglutide-treated rats had developed T2DM (overall p = .019). Liraglutide-treated rats also displayed lower fasting triglyceride (TG) concentrations and lower hepatic TG content, compared to control rats. Islet morphology was improved in liraglutide-treated rats, with significantly increased pancreatic insulin content (p < .05 vs. controls). Although GH treatment tended to increase body weight (and gastrocnemius muscle weight), there were no obvious effects on diabetes onset or other diabetes-related outcomes.ConclusionGH supplementation did not augment the anti-diabetic effects of liraglutide.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Chronic administration of the glucagon-like peptide-1 analogue, liraglutide, delays diabetes onset and improves lipids in a novel model of type 2 diabetes, the UCD-T2DM rat
    Havel, P. J.
    Cummings, B. P.
    Graham, J. L.
    Stanhope, K. L.
    Griffen, S. C.
    Nilsson, C.
    Knudsen, L. B.
    Raun, K.
    DIABETOLOGIA, 2009, 52 : S308 - S309
  • [22] The Anti-Diabetic, Lipidemic, And Pro-Inflammatory Effects of Metformin Versus Glibenclamide on T2DM Obese Patients
    Hamdy, Naglaa
    Abdel-Gabbar, Mohamed
    Sakr, Hader I.
    Gaber, Safy S.
    Kandeil, Mohamed
    Aziz, Ayman M. Abdel
    Ahmed, Osama M.
    EGYPTIAN JOURNAL OF CHEMISTRY, 2025, 68 (04): : 91 - 101
  • [23] Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats
    Cummings, Bethany P.
    Bettaieb, Ahmed
    Graham, James L.
    Kim, Jaehyoung
    Ma, Fangrui
    Shibata, Noreene
    Stanhope, Kimber L.
    Giulivi, Cecilia
    Hansen, Frederik
    Jelsing, Jacob
    Vrang, Niels
    Kowala, Mark
    Chouinard, Michael L.
    Haj, Fawaz G.
    Havel, Peter J.
    DISEASE MODELS & MECHANISMS, 2013, 6 (02) : 443 - 456
  • [24] Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice
    Xianlong Ye
    Jianying Qi
    Guiping Ren
    Pengfei Xu
    Yunzhou Wu
    Shenglong Zhu
    Dan Yu
    Shujie Li
    Qiang Wu
    Rasool Lubna Muhi
    Deshan Li
    Endocrine, 2015, 49 : 683 - 692
  • [25] Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice
    Ye, Xianlong
    Qi, Jianying
    Ren, Guiping
    Xu, Pengfei
    Wu, Yunzhou
    Zhu, Shenglong
    Yu, Dan
    Li, Shujie
    Wu, Qiang
    Muhi, Rasool Lubna
    Li, Deshan
    ENDOCRINE, 2015, 49 (03) : 683 - 692
  • [26] Potentiation of Acetylcholine-Induced Relaxation of Aorta in Male UC Davis Type 2 Diabetes Mellitus (UCD-T2DM) Rats: Sex-Specific Responses
    Akther, Farjana
    Razan, Md Rahatullah
    Shaligram, Sonali
    Graham, James L.
    Stanhope, Kimber L.
    Allen, Kaitlin N.
    Vazquez-Medina, Jose Pablo
    Havel, Peter J.
    Rahimian, Roshanak
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [27] Chronic Supplementation with the Antioxidant, α-Lipoic Acid (LA), Improves Glucose Tolerance in a Novel Diabetic Rat Model, the UCD-T2DM Rat, with Fructose Accelerated Diabetes Onset
    Cummings, Bethany P.
    Stanhope, Kimber L.
    Graham, James L.
    Griffen, Steven C.
    Havel, Peter J.
    DIABETES, 2009, 58 : A361 - A361
  • [28] Evaluation of the Antioxidant and Anti-Diabetic effects of Baicalin in Type 2 Diabetic Goto Kakizaki (GK) rats
    Tan, K. H. B.
    Siu, S. Y.
    Hsu, A.
    Huang, D. J.
    Waisundara, V. Y.
    PLANTA MEDICA, 2009, 75 (09) : 885 - 885
  • [29] A COST OF CONTROL ANALYSIS OF LIRAGLUTIDE VERSUS OTHER ANTI-DIABETIC THERAPIES IN THE TREATMENT OF PATIENT WITH TYPE 2 DIABETES IN CHINA
    Shen, A.
    Zhu, P.
    Ning, L.
    Fang, P.
    Xing, C.
    VALUE IN HEALTH, 2021, 24 : S80 - S80
  • [30] Transcriptomic Analysis of Insulin-Sensitive Tissues from Anti-Diabetic Drug Treated ZDF Rats, a T2DM Animal Model
    Kim, Yo Na
    Kim, Sangok
    Kim, Il-Yong
    Shin, Jae Hoon
    Cho, Sooyoung
    Yi, Sun Shin
    Kim, Wan Kyu
    Kim, Kyung-Sub
    Lee, Sanghyuk
    Seong, Je Kyung
    PLOS ONE, 2013, 8 (07):